gs010
Gene therapyexperimental
Clinical trial activity
7 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
6
Phase 3
4
Phase 4
0
Earliest trial started Feb 1, 2014 (NCT02064569)
Timeline
Indications
Studied for
Mechanism of action
- NADH-ubiquinone oxidoreductase chain 4Supplementation
MT-ND4 supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- gs010
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07303296 | Phase 2 | Jan 15, 2026 | GenSight Biologics |
| NCT03293524 | Phase 3 | Mar 12, 2018 | GenSight Biologics |
| NCT03406104 | Phase 3 | Jan 9, 2018 | GenSight Biologics |
| NCT02652780 | Phase 3 | Jan 1, 2016 | GenSight Biologics, University of London |
| NCT02652767 | Phase 3 | Jan 1, 2016 | Emory University, GenSight Biologics |
| NCT02064569 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2014 | CHNO des Quinze-Vingts, GenSight Biologics |
| NCT03672968 | N/A | — | GenSight Biologics |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GenSight Biologics | For profit | 7 | 7 | 3 | 2014 |
| CHNO des Quinze-Vingts | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Emory University | Academic/Hospital | 1 | 0 | 1 | 2016 |
| University of London | Academic/Hospital | 1 | 0 | 1 | 2016 |
4 organizations
Page 1 / 1